DE69932331D1 - Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit - Google Patents

Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit

Info

Publication number
DE69932331D1
DE69932331D1 DE69932331T DE69932331T DE69932331D1 DE 69932331 D1 DE69932331 D1 DE 69932331D1 DE 69932331 T DE69932331 T DE 69932331T DE 69932331 T DE69932331 T DE 69932331T DE 69932331 D1 DE69932331 D1 DE 69932331D1
Authority
DE
Germany
Prior art keywords
inhibiting
expression
sub
unit
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69932331T
Other languages
English (en)
Inventor
Eugen Uhlmann
Anuschirwan Peyman
Maria Teti
Ida Villanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of DE69932331D1 publication Critical patent/DE69932331D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69932331T 1998-04-17 1999-04-01 Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit Expired - Lifetime DE69932331D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98106989A EP0950709A1 (de) 1998-04-17 1998-04-17 Antisense Oligonukleotide zur Hemmung der Expression der Integrin alphaV Untereinheit
PCT/EP1999/002286 WO1999054456A1 (en) 1998-04-17 1999-04-01 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION

Publications (1)

Publication Number Publication Date
DE69932331D1 true DE69932331D1 (de) 2006-08-24

Family

ID=8231774

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69932331T Expired - Lifetime DE69932331D1 (de) 1998-04-17 1999-04-01 Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit

Country Status (9)

Country Link
EP (2) EP0950709A1 (de)
JP (1) JP2002512025A (de)
KR (1) KR100688045B1 (de)
AT (1) ATE332967T1 (de)
AU (1) AU3812599A (de)
BR (1) BR9909700A (de)
CA (1) CA2325821A1 (de)
DE (1) DE69932331D1 (de)
WO (1) WO1999054456A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1122262B1 (de) * 1998-10-16 2009-12-30 Otsuka Pharmaceutical Co., Ltd. Neovaskular-spezifische peptide
WO2002000877A2 (en) * 2000-06-29 2002-01-03 Mcgill University Antisense oligonucleotides to inhibit angiogenesis and/or metastasis
EP1197553A1 (de) * 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense-Nukleinsäure gegen das alphaV Integrin
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
EP1642585A1 (de) * 2004-09-27 2006-04-05 Immunotech S.A. Osteogene Oligonukleotide und deren Verwendungen
US9320775B2 (en) 2008-04-30 2016-04-26 Kci Licensing, Inc. Use of nucleic acids with reduced pressure therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung

Also Published As

Publication number Publication date
KR100688045B1 (ko) 2007-02-28
KR20010042796A (ko) 2001-05-25
EP1071764A1 (de) 2001-01-31
JP2002512025A (ja) 2002-04-23
EP0950709A1 (de) 1999-10-20
AU3812599A (en) 1999-11-08
BR9909700A (pt) 2000-12-26
EP1071764B1 (de) 2006-07-12
CA2325821A1 (en) 1999-10-28
ATE332967T1 (de) 2006-08-15
WO1999054456A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
PT731835E (pt) Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
DE50214715D1 (de) Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
YU91901A (sh) Oligonukleotidi za inhibiciju ekspresije humanog gena koji kodira eg5
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69932331D1 (de) Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit
PT775745E (pt) Aptameros inibidores de catepsina g
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
WO2003034985A3 (en) Telomerase interference
WO1999046375A3 (de) Menschliche nukleinsäuresequenzen aus prostatagewebe
ATE462791T1 (de) Parvovirus ns1 varianten
EP1248635A4 (de) Antisense-modulation der glykogen-synthase-kinase-3alpha-expression
BR0016347A (pt) Oligonucleotìdios antisenso
ATE449180T1 (de) Transglutaminase genprodukte
WO2001038586A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE60031262D1 (de) Menschliche promotoren des gaba b-rezeptors 1
DK1537210T3 (da) Decoy-oligonukleotid-inhibering af CD40-ekspression
ZA200102776B (en) Nucleotide sequences that code for the rpIK gene and methods of use thereof.
ES1049154Y (es) Utensilio para eliminacion de durezas de la piel.
AU2002248411A1 (en) Antisense modulation of protein phosphatase 2 catalytic subunit alpha expression

Legal Events

Date Code Title Description
8332 No legal effect for de